---
schema_version: "secwatch.filing_event.v1"
accession: "0000921299-25-000007"
form_type: "8-K"
ticker: "KYNB"
cik: "0000921299"
company_name: "KYNTRA BIO, INC."
filed_at: "2025-09-05T23:59:59+00:00"
generated_at: "2026-05-17T08:11:05.187412+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# FibroGen completes sale of China business to AstraZeneca for ~$220M; repays $81M term loan

## Summary
- Sale price ~$220M: $85M enterprise value plus ~$135M net cash held in China.
- Net cash received $210.4M; transaction costs $7.7M; net assets sold $138.9M.
- Pro forma cash and equivalents rise to $145M from $23M; pro forma deficit narrows to $1.684B.
- Repaid $80.9M to MSTV, including $73.7M term loan balance and $6.8M loss on debt extinguishment.
- Released $142.9M deferred revenue related to China single performance obligation.

## SEC filing metadata
- accession: 0000921299-25-000007
- form_type: 8-K
- ticker: KYNB
- cik: 0000921299
- company_name: KYNTRA BIO, INC.
- filed_at: 2025-09-05T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921299/000092129925000007/0000921299-25-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921299/000092129925000007/fgen-20250829.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000921299-25-000007
- JSON: https://secwatch.observer/filing/0000921299-25-000007.json
- Plain text: https://secwatch.observer/filing/0000921299-25-000007.txt

## Key facts
- M&A Transactions
  KYNTRA BIO, INC. completed a disposition involving AstraZeneca Treasury Limited for approximately $220 million (closed 2025-08-29).
  - Action: disposition
  - Counterparty: AstraZeneca Treasury Limited
  - Consideration: approximately $220 million
  - Closing: 2025-08-29
  source text: sold all of the issued and outstanding equity interests of FibroGen International (Hong Kong) Ltd. to AstraZeneca, for approximately $220 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/921299/000092129925000007/0000921299-25-000007-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.